Antibody Discovery Platform

About Partillion Bioscience

Partillion Bioscience, founded in 2020 and based in Los Angeles, is a private, pre-revenue platform company pioneering tools for functional single-cell analysis. Its award-winning Nanovial technology allows researchers to link a cell's secretory function (e.g., cytokine or antibody production) with its phenotype and genotype in a massively parallel, cost-effective format compatible with standard flow cytometers. The company is targeting the high-growth cell therapy and biologics discovery markets by providing a flexible reagent platform to improve the identification and characterization of potent therapeutic cells and antibodies.

About Augmenta Bioworks

Augmenta Bioworks, founded in 2021 and based in San Francisco, is a private, pre-clinical stage biotech leveraging synthetic biology to decode the human immune system. The company's core technology, DeepGrid™, combines advanced automation, microfluidics, high-throughput sequencing, and computational analysis to pinpoint rare, protective immune cells from which novel therapeutics can be derived. Augmenta operates a platform-plus-partnership business model, collaborating with pharmaceutical and biotech companies to discover antibodies, cell therapies, and immune modulators, positioning itself at the intersection of biologics discovery and personalized immunology.

Therapeutic Areas